Beacon Medical Interchange

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Beacon Medical Interchange

beaconmedic.com

Lung
Testicular
Prostate
Renal Cell
Bladder
Gastrointestinal
General

Playback speed

10 seconds

Will Immunotherapy Shift Treatment Balance for Borderline Resectable Stage III NSCLC?

By Beacon Medical Interchange FEATURING Jack West

247 views

November 2, 2018

Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for ...
read more ↘ durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.
↖ read less

0 Comments